Serum apelin and ADMA levels in type 2 diabetics with and without vascular complications

Karakoç A., Sahin A., Polat E. S., Aliyev E., Yildirim A., Bakan N., ...Daha Fazla

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, cilt.10, sa.2, 2016 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.dsx.2016.03.005
  • Dergi Adı: DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Anahtar Kelimeler: ADMA, Apelin, Type 2 diabetes mellitus, ASYMMETRIC DIMETHYLARGININE, PLASMA APELIN, RISK-FACTORS, DYSFUNCTION, INHIBITOR, METFORMIN, MORTALITY, ARGININE
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Hayır

Özet

Aims: Type 2 diabetes mellitus (T2DM) is a metabolic and chronic disease which is characterized by hyperglycemia, and that is the major causes of various micro and macrovascular complications. Asymmetrical dimethylarginine (ADMA), formed by the hydrolysis of proteins containing methylated arginine residues, is an endogenous inhibitor of nitric oxide synthase (NOS), which oxidize L-arginine to citruline and nitric oxide (NO), related to hyperinsulinaemia and hyperlipidaemia. Apelin is a recently discovered peptide, present in a number of tissues and play role in insulin sensitivity improvement. In this study, our aim was to determine the levels of apelin and ADMA with glycated haemoglobin (HbA1c) in type 2 diabetic patients with or without vascular complications.